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two granulosa cancer cell lines: the juvenile form (COV434) 
and the adult form (KGN).
Results ObR gene expression in cancer cell lines was 
50% higher than in the non-cancer cells. Lan-1 and Lan-2 
decreased ObR expression in COV434, while it had no 
effect in KGN cells. Higher ERβ expression in non-cancer 
and higher ERα expression in both cancer cell lines was 
noted. SHLA and Lan-1 changed the ratio towards greater 
expression of ERβ, characteristic of non-cancer granulosa 
cells. All ObR antagonists in HCrC1 and KGN but only 
Lan-2 in COV434 reversed leptin-stimulated proliferation. 
In both non-cancer and cancer granulosa cells, leptin acts as 
a cyclinD/cdk4, cyclin A/cdk2 and E2F inhibitor.
Conclusion These results indicate that SHLA and Lan2 
are promising leptin receptor inhibitors that can eliminate 
the negative effects of leptin. These compounds should 
be considered in further ex  vivo studies on the cancer 
microenvironment.
Abstract 
Purpose There are no data showing a direct correlation 
between obesity and increased blood leptin levels with 
folliculoma. Moreover, folliculoma is not the best studied 
among other ovarian cancer types. We investigated whether 
oestradiol can modulate ObR expression in some oestro-
gen-responsive tissues and that leptin exerts its activity not 
only via the leptin receptor but also through cross talk with 
other signalling systems. We hypothesise that blocking ObR 
expression could be a novel treatment for gonadal ovarian 
cancer.
Methods We evaluated the effect of SHLA, Lan1 and 
Lan2 blockers on cell proliferation (BrdU incorporation 
assay), ObR and ERα/β gene expression (qPCR), oestra-
diol secretion (ELISA) and cell cycle protein expression 
(Western blot) in the non-cancerous cell line HGrC1 and 
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Introduction
Leptin is a small (16 kDa) protein produced and secreted by 
adipose tissue, which is involved in appetite regulation, bone 
formation and reproductive function. Recent studies have 
demonstrated that this hormone stimulates growth, migra-
tion, invasion and angiogenesis in tumour cell models, sug-
gesting that leptin is capable of promoting an aggressive can-
cer phenotype [1]. Epidemiological studies have indicated 
a positive correlation between obesity and an increased risk 
of several types of cancer [2]. Serum leptin levels have been 
reported to be higher in overweight and obese women than 
in women with normal weight. In obese individuals, leptin 
levels can reach 40 ng/mL, which is up to ten times higher 
than in normal weight people [3, 4]. Cancer risk is higher 
among overweight and obese people, with an increased risk 
of 16 and 30%, respectively [5]. Moreover, leptin and its 
receptors are over-expressed in different human cancers [1]. 
Leptin has been proposed as one of the six markers of ovar-
ian cancer [6]. Uddin et al. revealed a significant associa-
tion between ObR overexpression and poor survival rates in 
59.2% of epithelial ovarian cancer cases [7].
Granulosa cell tumours constitute the second largest 
group of ovarian tumours (approximately, 25–30%), with 
tumours derived from epithelial cells accounting for approxi-
mately 70% [8]. Granulosa cell tumours can be divided into 
two histopathological forms: a mature form, diagnosed most 
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frequently in peri-menopausal women (95%), and a juvenile 
form, diagnosed in young women and girls who have aged 
prematurely (5% of cases) [9]. Despite the fact that granu-
losa cell tumours can be successfully treated by surgery, 
relapses are often observed and further adjuvant treatment 
is still not possible.
To our knowledge, there are no data showing a direct 
correlation between obesity and folliculomas. Moreover, fol-
liculoma is not well studied among the ovarian cancer types, 
although both the short (ObRa) and long (ObRb) forms of 
the leptin receptor are present in human granulosa cells [10, 
11]. Löffler et al. [10] showed that, in polycystic ovaries, 
leptin-positive cells were noted both in the hypertrophied 
theca layer and in the luteinised granulosa layer. Taking into 
consideration that leptin at a supraphysiological concentra-
tion, as noted in obese women, has stimulatory effects on 
testosterone secretion characteristic of polycystic ovarian 
syndrome correlated with obesity [12], we hypothesised that, 
as in the case of epithelial ovarian cancer, ObR overexpres-
sion in granulosa cell tumours could be correlated with the 
incidence of granulosa cell cancer, and leptin receptor block-
ers might be used as an adjuvant therapy.
Currently, several groups of scientists are working on 
the synthesis of molecules that block ObR. A number of 
leptin receptor antagonists have been synthesised for thera-
peutic use, with several completing pre-clinical testing 
[13], indicating their possible use in anticancer therapy. In 
previous studies using different epithelial cancer cell lines, 
we showed that SHLA and quadruple leptin mutein, Lan2 
(L39A/D40A/F41A/I42A), had no effect on non-cancerous 
HOSEpiC cell proliferation [14]. However, both antagonists 
reversed the stimulatory effect of leptin on metastatic carci-
noma CaOV-3 cell proliferation to control levels and even 
below control levels in chemoresistant OVCAR-3 cells. Lep-
tin receptor antagonists have been investigated in breast and 
prostate cancers, which mainly are hormone dependent. It 
has been shown that Aca1, Allo-aca and D-ser can inhibit 
leptin-stimulated proliferation in MCF-7 breast cancer cells 
[15]. Another leptin receptor antagonist, LDFI (Leu-Asp-
Phe-Ile), is also able to inhibit the proliferation of MCF-7 
cells in vitro and in vivo [16]. The antagonist Lan1 is able 
to inhibit the phosphorylation of leptin-signalling proteins 
Jak2, ERK1/2 and Akt, in PC3 and DU145 prostate cancer 
cell lines [17]. In a previously published study using epithe-
lial ovarian cancer cell lines, we investigated the effect of 
SHLA and Lan2 on the JAK/Stat3, MAPK/ERK and PI3K/
Akt pathways and showed an inhibitory effect of SHLA on 
all tested signalling proteins in OVCAR-3 cells and of Lan2 
on Stat3 and ERK1/2 proteins in CaOV-3 cells [14]. These 
data point to a similar signalling pathway in the antagonistic 
effects of leptin receptor blockers.
In the present study, we evaluated the effect of leptin 
and three of its receptor antagonists: Lan1 (L39A/D40A/
F41A mutant), Lan2 (L39A/D40A/F41A/I42A mutant) and 
SHLA (D23L/L39A/D40A/F41A mutant) on leptin and 
oestradiol receptor gene and protein expression, cell pro-
liferation including cell cycle protein expression, caspase-3 
activity and oestradiol secretion in two granulosa tumour 
cell lines. The two cell lines were COV434, representing 
the juvenile form of granulosa tumour, and the steroidogenic 
human ovarian granulosa-like tumour (KGN), representing 
the adult type of this cancer (corresponding to peri- to post-
menopausal age). The human immortalised non-luteinised 
granulosa cell line HGrC1 was used as the control.
Based on the fact that leptin exerts its activity not only 
through the leptin receptor (ObR), but also through cross 
talk with other signalling systems implicated in tumour 
genesis [18, 19], in this study we focused our attention on 
the relationship between the leptin/ObR axis and oestrogen 
receptors (ERα/β).
Taking into consideration that oestradiol can modulate 
ObR expression in some oestrogen-responsive tissues, we 
hypothesised that blocking ObR expression could be a novel 
treatment for granulosa ovarian cancer.
Materials and methods
Reagents
Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12 
(DMEM/F-12) was obtained from Gibco by Thermo Fisher 
Scientific (Waltham, MA, USA). DMEM, foetal bovine 
serum (FBS, heat inactivated), penicillin and streptomycin 
were obtained from Sigma Chemical Co. (St. Louis, MO, 
USA). All applied media were oestradiol free. Leptin was 
obtained from Sigma Chemical Co. (St. Louis, MO, USA). 
Leptin receptor antagonists (SHLA, Lan1 and Lan2) were 
obtained from Protein Laboratories Rehovot (PLR) Ltd. 
(Rehovot, Israel). All antagonists have the same specificity. 
They interact with the cytokine homology domain 2 in the 
leptin receptor and do not interact with IGD (immunoglob-
ulin-like domain) of the receptor, as the 39–40, 39–41 or 
39–42 Ala mutation abolished this interaction [20].
Cell culture
HGrC1 (human non-luteinised granulosa cell line) cells 
were a gift from Dr Ikara Iwase (Nagoya University, Japan) 
and cultured according to the protocol described by Baya-
sula et al. [21]. HGrC1 may possess the characteristics of 
granulosa cells in early stage follicles. A human immor-
talised non-luteinised granulosa cell line (HGrC1) origi-
nally derived from mural granulosa cells expresses the 
FSH receptor and is responsive to the transforming growth 
factor (TGF)-β superfamily and FSH, retaining its original 
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granulosa cell character and function. HGrC1 might also 
be capable of growth transition from a gonadotrophin-inde-
pendent status to gonadotrophin-dependent one, but they are 
not capable of undergoing luteinisation.
COV434 cells were obtained from the Sigma Chemical 
Co. (St. Louis, MO, USA). The biological characteristics 
of this cell line include production of 17β-oestradiol in 
response to FSH, absence of the LH receptor, no luteinisa-
tion capability and the presence of specific molecular mark-
ers of apoptosis enabling the induction of follicular atresia 
[22].
KGN cells were obtained from Masatoshi Nomura and 
Hajime Nawata, Kyushu University, Japan. With luteinisa-
tion capability, they constitute a useful model for under-
standing the regulation of steroidogenesis, cell growth and 
apoptosis in human granulosa cells [23].
HGrC1 and COV434 cells were routinely cultured in 
DMEM + 2 mM glutamine + 10% FBS. KGN cells were 
routinely cultured in DMEM/F-12 + 10% FBS. Cells were 
grown in 75 cm2 tissue culture dishes (Nunc, Denmark) in a 
37 °C incubator with a humidified mixture of 5%  CO2:95% 
air.
Experimental procedure
qPCR analysis
Basal ObR gene expression and expression of the ObR 
gene under the influence of leptin and leptin antagonists 
was determined by qPCR. Cells were seeded into 96-well 
culture plates at a density of 5 × 103 cells/well (HGrC1), 
8 × 103 cells/well (COV434) and 1.5 × 104 cells/well (KGN) 
taking into consideration the size of the cells and the popula-
tion doubling time. The next day, the medium was changed 
and cells were treated with leptin at a dose of 40 ng/mL 
and SHLA, Lan1 and Lan2 at a dose of 1000 ng/mL with 
leptin at a dose of 40 ng/mL for 24 h. Doses of leptin were 
chosen based on literature data [3, 4]. Total RNA isolation 
and cDNA synthesis was performed using the TaqMan Gene 
Expression Cell-to-CT Kit (Applied Biosystems, Carlsbad, 
CA, USA) in accordance with the manufacturer’s proto-
col. Amplifications were performed using the StepOnePlus 
system (Applied Biosystems, Carlsbad, CA, USA) and the 
TaqMan Leptin Receptor primer (Cat. No. Hs00174497_
m1), oestrogen receptor α primer (Hs00174860) and oestro-
gen receptor β primer (Hs01100353) in combination with the 
TaqMan Gene Expression Master Mix (Applied Biosystems, 
Carlsbad, CA, USA), in accordance with the manufacturer’s 
instructions.
A PCR was performed using a final volume of 20 μL, 
including 100 ng/reaction cDNA. PCR conditions were 
as follows: pre-incubation (2 min at 50 °C and 10 min at 
95 °C), amplification for 40 cycles (15 s at 95 °C and 1 min 
at 60 °C). The relative expression of genes was normalised 
against the endogenous reference gene GAPDH (Human 
GAPD Endogenous Control, number 4333764F) (ΔCq) and 
converted to relative expression using the  2−ΔΔCq method. 
The results are expressed as relative values (RQ).
Western blot analysis
Cells were plated into 24-well plates at a density of 2.5 × 104 
(HGrC1 cells), 3 × 104 (COV434 cells) and 6 × 104 (KGN 
cells) and allowed to attach overnight. The following day, 
the media were changed and cells were treated with 40 μg/
mL leptin alone or in combination with 1000 μg/mL SHLA, 
Lan1 or Lan2. To examine cell cycle protein expression, 
cells were incubated for 48 h. After incubation, cells were 
washed with ice-cold PBS and lysed with Laemmli lysis 
buffer (Sigma Chemical Co., St. Louis, MO, USA). The 
lysed cells were then scraped, transferred to microtubes and 
stored at −70 °C until analysis.
Prior to analysis, samples were sonicated and centrifuged 
at 15,000×g for 15 min at 4 °C. The quantity of protein 
was determined using the Bradford method and the clear 
supernatant was used for electrophoresis. Equal amounts of 
protein (100 µg) from each treatment group were separated 
by SDS-PAGE and transferred to PVDF membranes using 
a Bio-Rad Mini-Protean 3 apparatus (Bio-Rad Laborato-
ries Inc., Hercules, CA, USA). The blots were blocked for 
1 h in 5% BSA with 0.1% Tween-20 in 0.02 M TBS buffer. 
Blots were incubated overnight with primary antibodies spe-
cific to ObR (ab5593, Abcam, Cambridge, Great Britain) 
at a dilution of 1:2000, cyclin D1 (#2978, Cell Signaling 
Technology Inc., Beverly, MA, USA), cdk4 (#12790), cdk2 
(#2546), cyclin A2 (#4656) at a 1:1000 dilution and E2F-1 
(sc-251 Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA), E2F-2 (sc-633), ERα (sc-8002) and ERβ (sc-6822) 
at a dilution of 1:200. After incubation with the primary 
antibody, the membranes were washed three times with 0.1% 
Tween-20 in 0.02 M TBS buffer and incubated for 1 h with 
an appropriate horseradish peroxidase-conjugated secondary 
antibody (#7074 or #7076, Cell Signaling Technology Inc., 
Beverly, MA, USA; dilution 1:2000).
β-Actin was used as an internal loading control; mem-
branes were washed for 30 min in stripping buffer (0.25 M 
glycine, 1% SDS, pH 2) and reprobed by overnight incu-
bation with primary antibodies specific to β-actin (A5316, 
Sigma Chemical Co., St. Louis, MO, USA; dilution 1:2000) 
and for 1 h with a horseradish peroxidase-conjugated sec-
ondary antibody (P0447 DAKO, Glostrup, Denmark; dilu-
tion 1:5000).
Immunopositive bands were visualised using Western 
Blotting Luminol Reagent (Santa Cruz Biotechnology Inc., 
Santa Cruz, CA, USA) and ChemiDoc™ XRS+ System 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Relative 
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levels of protein expression were determined using ImageJ 
software (US National Institutes of Health, Bethesda, MD, 
USA). Individual protein levels were normalised to β-actin 
controls and the ratio of protein to β-actin was normalised 
to 1 in the untreated control group.
Cell proliferation BrdU assay
DNA synthesis in proliferating cells was determined by 
measuring bromodeoxyuridine (BrdU) incorporation with 
the commercial Cell Proliferation ELISA System (Roche 
Molecular Biochemicals, Mannheim, Germany). The 
cells were seeded in 96-well culture plates at a density of 
5 × 103 cells/well (HGrC1), 8 × 103 cells/well (COV434) 
and 1.2 × 104 cells/well (KGN). Leptin was added at a con-
centration of 40 ng/mL. Leptin receptor antagonists were 
added at concentrations of 10, 100 or 1000 ng/mL, with 
leptin at a concentration of 40 ng/mL. Cells were cultured 
for 48 h with repeated exposure; the culture medium was 
changed daily and fresh compounds added. After 48 h, the 
medium was removed and cells were incubated for 3 h with a 
BrdU labelling solution, containing 10 µM BrdU. The assay 
was performed according to the manufacturer’s instruc-
tions. Absorbance values were measured at 450 nm using 
an ELISA reader (ELx808 BIO-TEK Instruments, Vinooski, 
VT, USA). The culture medium alone was used as a control 
for non-specific binding.
Caspase‑3 activity assay
HGrC1 cells were seeded in 96-well culture plates at a 
density of 5 × 103 cells/well, COV434 cells at a density of 
8 × 103 cells/well and KGN cells at a density of 1.2 × 104 
cells per well. Leptin receptor antagonists were added at 
concentrations of 10, 100 or 1000 ng/mL, with leptin at a 
concentration of 40 ng/mL. Cells were cultured for 48 h 
with repeated exposure. The culture medium was changed 
daily and fresh compounds were added. After exposure, the 
medium was removed and the plates were stored at −70 °C. 
Cells were lysed in buffer containing 50  mM HEPES, 
100 mM NaCl, 0.1% CHAPS, 1 mM EDTA, 10% glycerol 
and 10 mM DTT. The assay was carried out by adding 
20 M of Ac DEVD-AMC, a substrate for the fluorometric 
determination of caspase-3 activity. Reaction mixtures were 
incubated at 37 °C. After 3 h, fluorescence was measured 
at 360 nm excitation and 460 nm emission using a micro-
ELISA plate reader (Bio-Tek Instruments).
Oestradiol secretion performed by the ELISA method
HGrC1 cells were seeded in 96-well culture plates at a 
density of 5 × 103 cells/well, COV434 cells at a density of 
8 × 103 cells/well and KGN cells at a density of 1.2 × 104 
cells/well. Leptin receptor antagonists were added at concen-
trations of 10, 100 or 1000 ng/mL, with leptin at a concentra-
tion of 40 ng/mL. Cells were cultured for 48 h with repeated 
exposure. The culture medium was changed daily and fresh 
compounds were added. Androstenedione  (10−5 M) was 
used as a substrate for oestradiol production. After 48 h, the 
media were collected and stored at −20 °C until analysis. 
Oestradiol concentrations in the medium were measured by 
enzyme immunoassay (EIA) using a commercially available 
ELISA kit (DRG Diagnostic, Germany). All samples were 
run in duplicate in the same assay. The analytical sensitivity 
was 10.6 pg/mL. The intra-assay variation was 8.7–9.23%, 
and the inter-assay variation was 6.87–14.91%. The range of 
the oestradiol (E2) assay was 10.6–2000 pg/ml.
Statistical analysis
Data were expressed as mean ± SEM from the four inde-
pendent experiments performed in triplicate. Statistical anal-
yses were performed using GraphPad Prism 5. Data were 
analysed using a one-way analysis of variance (ANOVA) 
followed by Tukey’s honestly significant difference (HSD) 
multiple range test. A value of P < 0.05 was considered to 
be statistically significant.
Results
The action of SHLA, Lan1 and Lan2 
on leptin‑stimulated leptin receptor (ObR) gene 
and protein in different cell lines
The basal leptin receptor gene expression varied between 
different cell lines. Assuming the gene expression in HGrC1 
cell to be 1, ObR gene expression in COV434 and KGN cells 
was 50% higher (Fig. 1a), while there were no differences in 
ObR protein expression (Fig. 1b).
In non-cancerous HGrC1 cells, leptin (40  ng/mL) 
decreased ObR gene expression, had no effect on ObRb, but 
increased ObRa protein expression. In both cancer cell lines, 
COV434 and KGN, leptin slightly increased gene expression 
but had no effect on both ObRb and ObRa protein expression 
(Fig. 1c, d).
In HGrC1 cells, all three antagonists increased ObR gene 
expression (Fig. 2a), reversing the inhibitory effect of leptin 
on ObR gene expression (Fig. 1c), but had no effect on pro-
tein expression (Fig. 2b). None of the antagonists affected 
ObR gene expression in COV434 and KGN cells (Fig. 2c, 
e). The inhibitory effects of Lan1 and Lan2 on both forms 
of ObR protein expression were observed in COV434 cells 
(Fig. 2d). In KGN cells, none of the ObR antagonists inves-
tigated had an effect on ObR protein expression (Fig. 2f).
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The action of SHLA, Lan1 and Lan2 
on leptin‑stimulated expression of oestrogen receptor 
(ER) gene and protein in different cell lines
The basal expression of the ERβ form in HGrC1 cells was 
twofold greater than the ERα form at both the gene and pro-
tein levels (Fig. 3a, b). In contrast, in the cancer cell lines, 
both gene and protein ERβ expressions were higher than 
those of the ERα form (Fig. 3a, b).
Leptin (40 ng/mL) decreased both ERα and ERβ gene 
expression in HGrC1 cells, but had no effect on protein lev-
els. In cancer cells, the expression of ER gene (Fig. 3c) and 
protein (Fig. 3d) in COV434 and KGN cells was unchanged 
by the addition of leptin. 
In HGrC1 cells, all three leptin receptor blockers 
increased ERα gene expression, but had no effect on ERβ 
gene expression (Fig. 4a). None of the antagonists affected 
ERα protein expression, although an inhibitory effect of 
Lan1 and Lan2 on ERβ protein expression was observed 
(Fig. 4b). In COV434 cells, SHLA decreased ERα gene 
expression and ERβ protein expression, but had no effect on 
ERβ gene expression. Lan1 increased ERβ gene expression 
and decreased ERβ protein expression, while Lan2 had the 
opposite effect (Fig. 4c, d). In KGN cells, all three blockers 
failed to affect ERα gene expression (Fig. 4e) but reduced 
ERα protein level (Fig. 4f). No effect on ERβ gene or protein 
expression was observed in KGN cells (Fig. 4e, f).
Effect of leptin receptor antagonists on proliferation, 
caspase‑3 activity and oestradiol secretion
In HGrC1 cells, leptin increased cell proliferation (80%) but 
had no effect on caspase-3 activity and slightly increased 
estradiol secretion (30%). All three leptin receptor blockers 
decreased BrdU incorporation (Fig. 5a), except that Lan2 
at the highest concentration (1000 ng/mL; Fig. 5d) had no 
effect on caspase-3 activity. Lan1 (1000 ng/mL) and Lan2 
(10 and 100 ng/mL) reduced oestradiol secretion (Fig. 5g).
In COV434 cells, SHLA and Lan2 at dose 1000 ng/mL 
decreased BrdU incorporation, while Lan1 had no effect 
(Fig. 5b). None of the blockers investigated had an effect on 
caspase-3 activity (Fig. 5e) or oestradiol secretion (Fig. 5h).
Fig. 1  Basal expression of leptin receptor (ObR) a gene and b pro-
tein, and leptin action on ObR c gene and d protein expression in dif‑
ferent cell lines. Basal mRNA was evaluated by qPCR after 24 h of 
cell culture and by Western blot after 48 h. All the results were nor-
malised to HGrC1 (ObR expression) with a value equal to 1. Values 
are mean ± SEM. Statistically significant differences between groups 
are indicated by *(p < 0.05) and **(p < 0.01). Densitometry results 
were normalised to β-actin loading controls to obtain a band ratio. All 
values marked with **(p < 0.01) are significantly different from the 
control
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Fig. 2  Effect of leptin receptor antagonists (SHLA, Lan1 and Lan2) 
on leptin receptor (ObR) gene (a, c, e) and protein (b, d, f) expres-
sion. All values marked with *(p  <  0.05) are significantly different 
from control values. Values are mean ± SEM. Densitometry results 
were normalised to β-actin loading controls
Fig. 3  Expression of the oestrogen receptor (ER) α and β forms at a 
the gene and b protein levels in different cell lines and the action of 
leptin on ER c gene and d protein expression. Each point represents 
the mean  ±  SEM from three independent experiments. All values 
marked with *(p < 0.05) and **(p < 0.01) are significantly different 
between ERα and ERβ (a, b) or from control values (c, d). All values 
marked with *(p < 0.05) and ** (p < 0.01) are significantly different 
from control values. Densitometry results were normalised to β-actin 
loading controls
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In KGN cells, SHLA at the highest dose and Lan1 and 
Lan2 at doses 100 and 1000 ng/mL decreased BrdU incor-
poration (Fig. 5c). None of the three antagonists investi-
gated affected caspase-3 activity (Fig. 5f), except for Lan2, 
which at the highest concentration decreased oestradiol 
levels. SHLA and Lan1 had no effect on oestradiol secre-
tion (Fig. 5i).
Effect on leptin receptor antagonists on selected cell 
cycle protein expression
In HGrC1 cells, leptin increased cdk4 and cdk2 protein 
expression and had no effect on cyclin D1 and A2. No 
effect on E2F1 or E2 was observed. Of the investigated lep-
tin receptor blockers, SHLA had no effect on selected cell 
cycle gene or protein expression. An inhibitory effect on 
Fig. 4  Effect of leptin receptor antagonists (SHLA, Lan1 and Lan2) 
on the expression of the oestradiol receptor α and β forms on the gene 
(a, c, e) and protein (b, d, f) level. Values are mean ± SEM. All val-
ues marked with *(p < 0.05) and **(p < 0.01) are significantly differ-
ent from control values
823Cancer Chemother Pharmacol (2017) 80:815–827 
1 3
cdk4 but not cyclin D was noted under the influence of Lan1. 
A marked inhibitory effect on cyclin A and cdk4 protein 
expression under the influence of Lan2 was noted. None 
of the antagonists investigated had an effect on E2F1 or E2 
(Fig. 6a).
In COV434 cells, leptin with the exception of a stimula-
tory effect on E2F2 had no effect on the expression of any 
other investigated cell cycle proteins. All three leptin recep-
tor blockers decreased cyclin D1 and cdk4 in the following 
order: SHLA < Lan1 < Lan2. In addition, SHLA decreased 
cyclin A2 protein expression, Lan1 cyclin A2 and cdk2 
expression, and Lan2 cdk2 protein expression. Of the three 
blockers studied here, only Lan2 had an inhibitory effect on 
E2F2 expression (Fig. 6b).
In KGN cells, leptin, with the exception of a slight inhibi-
tory effect on cdk2, had no effect on the expression any of 
the cell cycle proteins studied. All three blockers decreased 
the expression of cyclin D1 and cdk2, while Lan2 also 
reduced cdk4 expression and both Lan1 and Lan2 reduced 
E2F1 protein.
Discussion
This study clearly demonstrates twofold higher leptin recep-
tor gene and protein expression in cancer granulosa cell lines 
compared to non-cancer cell lines. Additionally, we found 
that leptin increased its own receptor gene expression only 
in cancer cell lines.
These results on both the short (ObRa) and long (ObRb) 
forms of the leptin receptor are in agreement with other 
studies demonstrating both forms of the leptin receptor in 
Fig. 5  Effect of leptin and leptin receptor antagonists (SHLA, Lan1 
and Lan2) on a–c cell proliferation (BrdU incorporation), d–f cas-
pase-3 activity and g–i oestradiol secretion. Each point represents 
the mean ± SEM from three independent experiments of four repli-
cates per treatment group. In a–f, values marked with *(p < 0.05) and 
**(p < 0.01) are significantly different from leptin values. In g–i, val-
ues marked with * are significantly different from control, while those 
indicated by #(p < 0.05) are significantly different from leptin
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granulosa cells [11, 24]. As described by us, higher ObR 
expression and a leptin-stimulatory effect on its own recep-
tor in cancer granulosa cells correspond with our previously 
published data [14] in epithelial ovarian cancer cells, sug-
gesting similar effects in both epithelial ovarian cancer and 
folliculoma. Increased expression of ObR, corresponding to 
higher risk, has also been described in cases of breast [1] and 
prostate cancer [25], both hormone-dependent cancer types. 
In ovarian cancer patients, high leptin levels are associated 
with poor treatment prognosis [26].
Cross talk between leptin and oestrogen receptors should 
also be taken into consideration. It was apparent that, in can-
cer cells, elevated ObR expression correlated with elevated 
ERα expression. The direct relationship between ObR and 
ER is still unresolved; however, the existence of cross talk 
between these receptors was examined. Fusco et al. [19] 
described a threefold increase in ERα expression in the pres-
ence of 100 ng/mL leptin. Different effects, dependent on 
the type of ER expression, have been described by Ray et al. 
[27] and Ozbay et al. [28], who showed that leptin increased 
the proliferation level to a greater extent in the ER+ breast 
cancer cell line T47-D than in ER− MDA-MB231 cells. 
This finding is in line with our results, as all investigated 
granulosa cell lines demonstrated a higher degree of prolif-
eration than in previously examined epithelial ovarian cell 
lines [14]. Physiologically, the primary sites of oestrogen 
receptors include the same areas where ObR are located 
[29]. Leptin can enhance aromatase activity, promoting 
oestrogen production from androstenedione in adipose 
tissue and hence stimulate the progression of oestrogen-
dependent breast cancer [30]. Furthermore, leptin enhances 
the activation of oestrogen receptor alpha (ERα) through 
the MAPK pathway in MCF-7 and HeLa cells [31]. In ER+ 
MCF-7 cells, chronic exposure to leptin has been found to 
result in a higher ERα/ERβ ratio, enhanced oestrogen tran-
scriptional activity, greater cell growth and resistance to the 
anti-oestrogen compound tamoxifen [32].
It is well known that leptin can directly affect ovarian 
function by its action on oestradiol secretion [33]. There 
have been a few studies on blocking leptin activity in the 
ovary and interactions with oestradiol secretion. Our results 
show that the leptin receptor antagonists SHLA and Lan1, 
at concentrations of 100 ng/mL, increased oestradiol (E2) 
secretion by the HGrC1 cell line, but had no effect on oestra-
diol secretion in granulosa cancer cells (except for Lan2, 
which decreased E2 secretion in KGN cells). The effect 
on ERα and ERβ expression was variable in this study. In 
HGrC1 cells, all antagonists decreased ERβ gene expression, 
but only Lan1 and Lan2 decreased protein levels. The block-
ers SHLA and Lan1 decreased ERα in juvenile COV434 
cells, while Lan1 and Lan2 had an effect in adult form KGN 
cells. These results suggest that, independently of the magni-
tude of ERα expression, Lan1 was sufficient in both types of 
cells. Our data are in agreement with Fusco et al. [19], who 
showed that leptin receptor silencing in MCF-7 breast cancer 
cells results in decreased ERα expression. The same authors 
reported that higher leptin levels are more strongly corre-
lated with ER+ breast cancer rather than ER−. In another 
study, Dupuis et al. [11] used the leptin receptor antagonist 
PEG-SMLA to demonstrate that inhibition of ObR impaired 
follicle rupture without affecting meiotic maturation of 
oocytes in ovarian follicles.
Fig. 6  Expression of cell cycle proteins in HGrC1, COV434 and 
KGN cell lines under the influence of leptin and leptin receptor 
antagonists. The representative blots of three experiments are shown 
in the panels. Cdk2, cyclin A, cdk4, cyclin D and E2F1 densitometry 
results were normalised to GAPDH loading controls to obtain band 
ratios. Values are mean ± SEM. All values marked with *(p < 0.05), 
**(p < 0.01) are significantly different from untreated control values. 
All values marked with #(p < 0.05), ##(p < 0.01) are significantly dif-
ferent from the values of leptin at 40 ng/mL
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Leptin, via direct action through ObR and additionally by 
enhancing the activation of oestrogen receptor alpha (ERα) 
through the MAPK pathway, induces cell proliferation. The 
data presented here show that leptin at a supraphysiological 
level induced cell proliferation in all investigated cell types, 
with the greatest effect observed in the normal granulosa 
cell line HGrC1 where proliferation reached 180% of the 
control. The mutagenic effect of leptin has been observed in 
various cell types, including breast cancer [33, 34], endo-
metrial cancer [35] and prostate cancer cells [25]. Kato et al. 
[36] showed that higher leptin levels (above 100 ng/mL) 
or longer incubation times are required to have an effect 
on proliferation. However, Fiedor and Gregoraszczuk [14] 
and Ptak et al. [37], using the same leptin concentration, 
described a similar effect on the proliferation of epithelial 
ovarian cancer cells.
All ObR antagonists used in this study reversed the lep-
tin-stimulatory effects on cell proliferation, although with 
varying degrees of success. In non-cancerous HGrC1 cells, 
the most potent antagonist was SHLA. In KGN cells, all 
three antagonists at all concentrations reversed leptin-stim-
ulated proliferation. Surprisingly, in the COV434 cell line, 
the effects of blockers were negligible. The use of leptin 
receptor antagonists has been well studied in breast cancer. 
There are reports of the inhibitory action of Aca-1 and Allo-
aca on leptin-stimulated proliferation of MCF-7 and MDA-
MB231 breast cancer cells [15], and D-Ser and DDD on the 
proliferation of MCF-7 cells [38]. Catalano et al. [16], using 
LDFI (leptin binding site I), showed the inhibitory effects 
on the leptin-induced growth of ERα-positive (MCF-7) and 
ERα-negative (SKBR3) breast cancer cells. Fusco et al. [19] 
demonstrated the inhibitory effects of a neutralising mono-
clonal antibody (9F8) on cell proliferation in the ER-positive 
MCF-7 cell line, but not in MDA-MB231 ER-negative cells. 
We previously described SHLA and Lan2 as a promising 
treatment for epithelial ovarian cell tumours [14]. To our 
knowledge, these are the first findings to indicate the pos-
sible use of ObR blockers in the treatment of folliculoma 
cancer.
Our results reveal that leptin at 40 ng/mL does not 
affect caspase-3 activity in non-luteinising cells HGrC1, 
but could decrease it in COV434 cells and to a small extent 
in KGN cells. Using granulosa cells, Sirotkin et al. [39] 
showed a stimulatory effect of leptin at a dose of 100 ng/
mL on Bax protein in human granulosa cells, suggesting 
that leptin can modulate apoptosis in human ovaries. The 
discrepancy in the findings may be due to the different 
concentrations of leptin. All the antagonists investigated 
here had no effect on caspase-3 activity in HGrC1 or KGN 
cells. Only Lan1 and Lan2, at the highest concentrations, 
restored caspase-3 activity close to the control level in 
COV434 cells. Previous experiments conducted in our 
laboratory have shown that, in epithelial ovarian tumours, 
leptin at 40 ng/mL alone or in combination of SHLA or 
Lan2 does not affect the activity of caspase-3, -8 or -9 
(unpublished data).
With regard to the mechanism of action of the ObR antag-
onists, we showed that, in non-cancer HGrC1 cells, Lan1 
and Lan2 decreased the expression of cyclin A2 and cdk4. 
In COV434 cells, all tested antagonists decreased cyclin D1 
and cdk4 protein expression, while Lan1 also decreased cyc-
lin A2 and cdk2, SHLA had an inhibitory effect on cyclin A, 
and Lan2 inhibited cdk2 expression. It is generally believed 
that the critical function of the cyclin A–Cdk2 complex is 
the phosphorylation of substrates that start DNA replication 
and co-ordinate the end of S-phase [40]. In KGN cells, only 
cyclin D1 and cdk2 were decreased by all leptin receptor 
blockers. Additionally, we observed an inhibitory effect of 
Lan1 and Lan2 on the expression of the transcription fac-
tor E2F1, suggesting that the anti-proliferative effect of this 
antagonist in ovarian cancer may be mediated, in part, by the 
down-regulation of E2F1. Our previously published results 
[14] concerning the action of leptin receptor antagonists 
on epithelial ovarian cancer cells showed that both antago-
nists studied decreased cdk2 and cdk4 protein expression 
in CaOV-3 and OVCAR-3 cells. Additionally, in CaOV-3 
cells, cyclin D1 expression decreased under the influence 
of SHLA and Lan2.
In summary, (1) in juvenile form of folliculoma, SHLA 
and Lan-1 increased ERβ expression, while in the adult form 
all blockers decreased ERα expression. As a consequence, 
the ratio moved towards greater expression of ERβ, charac-
teristic of non-cancer granulosa cells. (2) In both types of 
folliculoma, Lan1 and Lan2 acted as inhibitors of cyclinD/
cdk4, cdk2 and E2F. The ability of these cyclins to activate 
the cyclin-dependent kinase CDK4 is the most extensively 
documented mechanism for their oncogenic actions and pro-
vides an attractive therapeutic target.
In conclusion, taking into consideration that these 
results are based on experiments performed on cell lines, 
and did not consider the tumour microenvironment, further 
studies should be performed using explants of granulosa 
cancer from patients with folliculoma or the coculture of 
granulosa cancer cell line with fibroblasts, epithelial cells 
and other components of the tumour environment.
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